Results 31 to 40 of about 10,236,148 (357)

L-DOPA

open access: yesJournal of Parkinson’s Disease, 2017
Today we would find it difficult to place ourselves in the position of the physician or the patient prior to the L-DOPA era of Parkinson’s Disease (PD). David Marsden, the eminent British neurologist, neuroscientist and PD researcher of the second half of the last century and an eyewitness to that historical turning point, paints with few brush strokes,
openaire   +3 more sources

Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias

open access: yes, 2019
Introduction: Parkinson’s disease (PD), is a disorder debilitant characterized by the reduction of nigrostriatal dopaminergic neurons within the midbrain, specifically in the substantia nigra pars compacta, which results for the dopamine (DA) depletion ...
Lorenna Emília Sena Lopes (7860332)   +3 more
core   +1 more source

Inducing mutations through γ-irradiation in seeds of Mucuna pruriens for developing high L-DOPA-yielding genotypes

open access: yes, 2017
Purpose: To develop elite genotypes in Mucuna pruriens (L.) DC with high L-DOPA (L-3, 4 dihydroxyphenylalanine) yields, with non-itching characteristics and better adaptability by applying γ-irradiation.
Deepti Yadav (3365363)   +4 more
core   +1 more source

CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao   +7 more
wiley   +1 more source

l-3,4-Dihydroxyphenylalanine induces ptosis through a GPR143-independent mechanism in mice

open access: yesJournal of Pharmacological Sciences, 2016
Through its conversion to dopamine by aromatic l-amino acid decarboxylase (AADC), l-3,4-dihydroxyphenylalanine (l-DOPA) replenishes depleted brain dopamine in Parkinson's disease patients. We recently identified GPR143 as a candidate receptor for l-DOPA.
Suguru Ueda   +3 more
doaj   +1 more source

Dopa-responsive dystonia and hyperprolactinaemia : a novel association in two sisters [PDF]

open access: yes, 2007
Dopa-Responsive Dystonia (DRD) is a rare hereditary condition of childhood-onset dystonia which responds dramatically to treatment with levodopa. It was first described in 1971 as a "hereditary progressive basal ganglia disease with marked diurnal ...
Cachia, Mario J., Galea, Janabel
core  

Determination of l-dopa using electropolymerized 3,3′,3″,3‴-tetraaminophthalocyanatonickel(II) film on glassy carbon electrode

open access: yes, 2007
Electropolymerized film of 3,3′,3″,3‴-tetraaminophthalocyanatonickel(II) (p-NiIITAPc) on glassy carbon (GC) electrode was used for the selective and stable determination of 3,4-dihydroxy-l-phenylalanine (l-dopa) in acetate buffer (pH 4.0) solution.
Abraham John, S., Arumugam , Sivanesan
core   +1 more source

Zein‐Based Adhesives: Sustainable Extraction and Application in Bioadhesive Technologies

open access: yesAdvanced Engineering Materials, EarlyView.
Zein is extracted from corn gluten meal using a simple and scalable process with high yield (~90%). The resulting protein is applied in bioadhesives modified with Ca2+ and Fe3+ ions, exhibiting substrate‐dependent adhesion. The findings demonstrate competitive bonding performance and highlight the role of ionic interactions in tuning adhesion ...
Paula Bertolino Sanvezzo   +3 more
wiley   +1 more source

The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson’s Disease

open access: yesCells, 2020
Levodopa (L-DOPA) treatment in Parkinson’s disease is limited by the emergence of L-DOPA-induced dyskinesia. Such dyskinesia is associated with aberrant gene regulation in neurons of the striatum, which is caused by abnormal dopamine release from ...
Feras Altwal   +3 more
doaj   +1 more source

Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. [PDF]

open access: yesPLoS ONE, 2010
BackgroundRadiotracer imaging of the presynaptic nigrostriatal dopaminergic system is used to assess disease progression in Parkinson's disease (PD) and may provide a useful adjunct to clinical assessment during therapeutic trials of potential ...
Pierre-Olivier Fernagut   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy